These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17909805)

  • 21. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm.
    Stoch SA; Friedman E; Maes A; Yee K; Xu Y; Larson P; Fitzgerald M; Chodakewitz J; Wagner JA
    J Clin Pharmacol; 2009 Apr; 49(4):398-406. PubMed ID: 19246722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
    Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
    Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer.
    Zamboni WC; Combest AJ; DeLoia JA; Edwards RP; Bridges AS; Zamboni BA; Walko CM; Yu AY; Krivak TC; Kelley JL
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1255-62. PubMed ID: 21437702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
    Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
    Ando M; Saka H; Ando Y; Minami H; Kuzuya T; Yamamoto M; Watanabe A; Sakai S; Shimokata K; Hasegawa Y
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):552-8. PubMed ID: 15856233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
    Figg WD; Woo S; Zhu W; Chen X; Ajiboye AS; Steinberg SM; Price DK; Wright JJ; Parnes HL; Arlen PM; Gulley JL; Dahut WL
    J Urol; 2010 Jun; 183(6):2219-26. PubMed ID: 20399458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs.
    McEntee MC; Rassnick KM; Lewis LD; Zgola MM; Beaulieu BB; Balkman CE; Page RL
    Am J Vet Res; 2006 Jun; 67(6):1057-62. PubMed ID: 16740102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.
    Han B; Mao J; Chien JY; Hall SD
    Drug Metab Dispos; 2013 Jul; 41(7):1329-38. PubMed ID: 23584886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
    Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
    Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
    Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
    Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
    Cox MC; Low J; Lee J; Walshe J; Denduluri N; Berman A; Permenter MG; Petros WP; Price DK; Figg WD; Sparreboom A; Swain SM
    Clin Cancer Res; 2006 Aug; 12(15):4636-40. PubMed ID: 16899612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.
    de Jonge MJ; Dumez H; Kitzen JJ; Beuselinck B; Verweij J; Courtney R; Battista A; Brega N; Schöffski P
    Eur J Cancer; 2011 Jun; 47(9):1328-35. PubMed ID: 21439816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
    Bosch TM; Huitema AD; Doodeman VD; Jansen R; Witteveen E; Smit WM; Jansen RL; van Herpen CM; Soesan M; Beijnen JH; Schellens JH
    Clin Cancer Res; 2006 Oct; 12(19):5786-93. PubMed ID: 17020985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of docetaxel and topotecan in patients with advanced malignancies.
    Dubey S; Hutson P; Alberti D; Arzoomanian R; Binger K; Volkman J; Feierabend C; Wilding G; Schiller JH
    J Oncol Pharm Pract; 2005 Dec; 11(4):131-8. PubMed ID: 16595064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study.
    Diéras V; Lortholary A; Laurence V; Delva R; Girre V; Livartowski A; Assadourian S; Semiond D; Pierga JY
    Eur J Cancer; 2013 Jan; 49(1):25-34. PubMed ID: 22975213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer.
    Kim YH; Seo HY; Jeen YT; Kim HK; Shim BY; Yang J
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):253-60. PubMed ID: 18493761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
    LoRusso PM; Jones SF; Koch KM; Arya N; Fleming RA; Loftiss J; Pandite L; Gadgeel S; Weber BL; Burris HA
    J Clin Oncol; 2008 Jun; 26(18):3051-6. PubMed ID: 18565892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.